Clin Osteol 2010; 15(2): 68-74

Pleiotropic role of vitamin D and its active metabolites in the treatment of osteoporosisReview articles

P. Horák, M. Skácelová, M. Žurek, J. Zadražil

Keywords: vitamín D, kalcitriol, alfakalcidol, osteoporóza _ SUMMARY

Published: December 11, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P, Skácelová M, Žurek M, Zadražil J. Pleiotropic role of vitamin D and its active metabolites in the treatment of osteoporosis. Osteologický bulletin. 2010;15(2):68-74.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mellanby E. An experimental investigation of rickets. Lancet 1919;1:407-411. Go to original source...
    2. McCollum EV, Simmonds N, Becker JE, Shipley PG. Studies on experimental ric­ kets. XXI: an experimental demonstration of the existence of a vitamin which pro­ motes calcium deposition. J Biol Chem 1922;53:293-296. Go to original source...
    3. Butenandt A. Zur Geschichte der Sterin- und Vitamin-Forschung. Adolf Windaus zum Gedächtnis. J Nutr 1960;72:645-651. Go to original source...
    4. Holick MF. Vitamin D, photobiology, metabolism, mechanism of action, and cli­ nical appliactions. In: Primer on the metabolic bone disases and disorders of mi­ neral metabolism, 5th Edition, Lippincott,Philadelphia 2003; pp.129-137.
    5. Tsai KS, Heath H, Kumar R et al. Impaired vitamin D metabolism with aging in women: possible role in pathogenesis of senile osteoporosis. J Clin Invest 1984;73: 1668-1672. Go to original source...
    6. Avioli LV. Vitamin D and the D hormones, alfacalcidol and calcitriol, as therape­ utic agents for osteoporotic populations. Calcif Tissue Int 1999;65:292-294. Go to original source...
    7. Ichikawa F, Sato K, Nanjo M et al. Mouse primary osteoblasts express vitamin D 25-hydroxylase mRNA and convert 1a,25-dihydroxyvitamin D3. Bone 1995;16: 129-135. Go to original source...
    8. Haussler MR. Vitamin D receptors: nature and function. Annu Revs Nutr 1986;6:527-562. Go to original source...
    9. Pavek P, Pospechova K, Svecova L et al. Intestinal cell-specific vitamin D recep­ tor (VDR)-mediated transcriptional regulation of CYP3A4 gene. Biochem Pharmacol 2010;79:277-287. Go to original source...
    10. De Luca H. The vitamin D story: a collaborative effort of basic science and clini­ cal medicine. Fed Proc Am Soc Exp Biol 1988;2:1083-1086.
    11. Pike JW. Vitamin D3 receptors: structure and function in transcription. Anuu Revs Nutr 1991;11:189-216. Go to original source...
    12. Iqbal SJ. Vitamin D metabolism and the clinical aspects of measuring metaboli­ tes. Ann Clin Biochem 1994;31:109-124. Go to original source...
    13. Adorini A, Penna G. Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 2008;4:404-412. Go to original source...
    14. Heaney RP, Barger Lux MJ, Dowel MS, Chen TC, Holick MF. Calcium absorpti­ ve effect of vitamin D and its major metabolites. J Clin Endrocrinolo Metab 1997;82:4111-4116. Go to original source...
    15. Hart GR. Overview of vitamin D measurement and methodologies. Immuno­ diagnostic systems 2005;2:1-9.
    16. Zittermann A Vitamin D in preventive medicine: are we ignoring evidence? Br J Nutr 2003;89:552-572. Go to original source...
    17. Hart GR. Medical conditions associated with vitamin D deficiency and the clini­ cal consequences. Review Series 2004;1:1-10.
    18. Geusens P, van Brusel MS, Lems WF. Osteoporosis and fracture risk: pathogene­ sis, epidemiology, clinical aspects and diagnosis. In: Bijlsma JWJ ed. Eular com­ pendium on rheumatic diseases, BMJ Publishing Group, London 2009; pp.523-538.
    19. McKenna MJ. Differences in vitamin D status between countries in young adults and the elderly. Am J Med 1992;93:69-77. Go to original source...
    20. Krexner E, Resch H, Pietschmann P et al. Vitamin D status in residents of a long-term-care geriatric hospital in Vienna. Osteologie 1996;5:13-18.
    21. Chapuy MC, Durr F, Chapuy P. Age-related changes in parathyroid hormone and 25 hydroxycholecalciferol levels. J Gerontol 1996;38:19-22. Go to original source...
    22. Chapuy MC, Chapuy C, Meunier PJ. Calcium and vitamin D supplements: effects on calcium metabolism in elderly people. Am J Clin Nutr 1987;46:324-328. Go to original source...
    23. Chapuy MC, Arlot ME, DuBoef F et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992;327:1637-1642. Go to original source...
    24. Vieth R, Cole DE, Hawker GA et al. Wintertime vitamin D insufficiency is com­ mon in young Canadian women, and their vitamin D intake does not prevent it. Eur J Clin Nutr 2001;55:1091-1097. Go to original source...
    25. Välimäki VV, Alfthan H, Lehmusklallio E et al. Vitamin D status as a determinant of peak bone mass in young finnish men. J Clin Endocrinol Metabol 2004;89: 76-80. Go to original source...
    26. Holick MF, Chen TC. Vitamin D deficiency: A world wide problem with health consequences. A J Clin Nutr 2008;87:1080-1086. Go to original source...
    27. Lips P, Hosking D, Lippuner K et al. The prevalence of vitamin D inadequacy amongst women with osteoporosis: an international epidemiological investigation. J Intern Med 2006;260:245-254. Go to original source...
    28. Cantorna MT, Mahon BD. D hormone and immune system. J Rheumatol 2005; 32, Suppl. 1:11-20.
    29. Verhaar HJJ, Samson MM, Jansen PAF et al. Muscle strength, functional mobili­ ty and vitamin D in older women. Aging Clin Exp Res 2000;12:455-460. Go to original source...
    30. Ringe J, Schacht E. Prevention and therapy of osteoporosis: the roles of plain vi­ tamin D and alfacalcidol. Rheumatol Int 2004;24:189-197. Boland R. Role of vi­ tamin D in skeletal muscle function. Endocrin Rev 1986;784:434-448. Go to original source...
    31. Bischoff HA, Borchers M, Gudat F et al. In situ detection of 1,25 diydroxyvitamin D receptor in human skeletal muscle tissu. Histochem 2001;33:434-448. Go to original source...
    32. Seino I, Tanaka H, Yamaoka K, Yabucchi H. Circulating 1a,25-dihydroxyvitamin D3 levels after a single dose of 1a,25-dihydroxyvitamin D3 or 1a-hydroxyvitamin D3 in normal men. Bone Miner 1987;2:479-485.
    33. Scharla SH, Schacht E, Bawey S et al. Pleiotropic effects of 1-alfa-hydroxyvitamin D (alfacalcidol) in patients with rheumatoid arthritis. Arthritis Rheum 2003;23:268-274.
    34. Amin S, LaValley MP, Simms RW et al. The role of vitamin D in corticosteroidinduced osteoporosis: a metaanalytic approach. Arthritis Rheum 1999;42: 1740-1751. Go to original source...
    35. P^padimitropoulos E, Wells G, Shea B. Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocrine Reviews 2002;23:560-569. Go to original source...
    36. Ringe JD. Active vitamin D metabolites in glucocorticoid-induced osteoporosis. Calcif Tissue Int 1997;60:124-127. Go to original source...
    37. Ringe JD, Coster A, Meng T et al. Treatment of glucocorticoid-induced osteopo­ rosis with alfacalcidol/ calcium versus vitamin D/calcium. Calcif Tissue Int 1999;63:337-340. Go to original source...
    38. Ringe JD, Faber H. Calcium and vitamin D in the prevention and treatment of glu­ cocorticoid-induced osteoporosis. Clin Exp Rheumatol 2000; 5 (Suppl. 21):44-48.
    39. Nuti R, Bianchi G, Brandi ML et al. Superioity of alfacalcidol to vitamin D plus calcium in lumbar mineral density in postmenopausal osteoporosis. Rheumatol Int 2006;26:445-453. Go to original source...
    40. Richy F, Ethgen O, Bruyere O, Reginster JY. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis oftheir ef­ fects on bone mineral density and fracture rate. Osteoporosis Int 2004;15:301-310. Go to original source...
    41. Richy JD, Schacht E, Bruyere O et al. Vitamin D analogs versus native vitamin D preventing bone loss and osteoporosis related fractures: A comparative meta-analysis. Calcif Tissue Int 2005;76:176-186. Go to original source...
    42. Ringe JD, Faber H, Fahramand P, Schacht E. Alphacalcidol versus plain vitamin D in treatment of glukortikoid/inflammation-induced osteoporosis, J Rheumatol 2005; 32 (Suppl 76):33^0.
    43. Sambrook PN, Kotowitz M, Nash P et al. Prevention and treatment of glucocoroid induced osteoporosis: a comparison calcitriol, vitamin D plus calcm and alend­ ronate plus calcium J Bone Min Res 2003;18:919-924. Go to original source...
    44. Richy F, Dukas L, Schacht E. Differential effects of D hormon analog and native vitamin D on the risk of falls. A comparative metaanalysis. Calcif Tissue Int 2008;82:102-107. Go to original source...
    45. Dukas L, Schacht E, Mazor Z, Stähelin HB. Treatment with alphakalcidol in el­ derly people significantly decreases the high risk of falls associated with a low creatinine clearance of < 65 ml/min. Osteoporosis Int 2005;16:198-203. Go to original source...
    46. Ringe JD, Farahmand P, Schacht E, Rozehnal A Superiority of a combined treat­ ment of Alendronate and Alfakalcidol compared to the combination of Alendronate and plain vitamin D or Alphakalcidol alone in established postme­ nopausal or male osteoporosis (AAC-Trial). Rheumatol Int 2007;27:425-434. Go to original source...
    47. Kalvachová B. Vitamin D - nové poznatky a endokrinní mikrosystémy katcitriolu. Osteologický bulletin 2007;12:62-67.
    48. Masaryk P. Alfakalcidol a riziko pádov pri osteoporóze. Osteologický bulletin 2007; 12:53-57.
    49. Blahoš J. Treatment and prevention of osteoporosis. Wiener Medizinische Wochenschrift 2007;157:589-592. Go to original source...
    50. Štěpán J, Payer J, Abrahámová J. Stratifikace léčby postmenopauzální osteoporózy. Prakt Lék 2004;84:500-506.
    51. Blahoš J, Palička V, Býma S. Osteoporóza - doporučený diagnostický a léčebný postup pro všeobecné praktické lékaře 2006. Osteologický bulletin 2007;12:35-38.

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.